LatticeMLS
Menu

Module CC-11 · Version 1.0

Metabolic Syndrome and Continuous Glucose Monitoring

Place fasting glucose, lipids, and CGM-derived metrics into a metabolic-risk picture, learn which criteria version and glucose threshold a metabolic-syndrome classification depends on, and interpret an ambulatory glucose profile with attention to sensor data sufficiency and the difference between GMI and laboratory A1c.

Your next section

Start section 1

Read without an account. Sign in to save.

Who this module is for

Clinical laboratory scientists and laboratory trainees who report chemistry and CGM-adjacent results and field provider or patient questions about discordant values.

Learning objectives

  • Identify the laboratory measurements commonly used in metabolic-syndrome frameworks and name which criteria version and cut point apply to a given result set.
  • Explain time in range, mean glucose, glucose management indicator, variability, and sensor data sufficiency as read from an ambulatory glucose profile.
  • Recognize that CGM interstitial glucose, venous plasma glucose, and laboratory A1c answer related but different questions, and choose a defensible next laboratory action when they disagree.

How completion works

Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.

Sources

10 sources

  1. 1. American Diabetes Association. Section 2: Diagnosis and Classification of Diabetes. Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S27.

    Source note · professional society guidance

  2. 2. American Diabetes Association. Section 6: Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises. Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S132.

    Source note · professional society guidance

  3. 3. National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), NIH/NHLBI, 2001 (with 2004 update).

    Source note · consensus standard

  4. 4. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.

    Source note · consensus standard

  5. 5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350.

    Source note · professional society guidance

  6. 6. FDA Center for Devices and Radiological Health. 510(k) Decision Summary, Dexcom G7 Continuous Glucose Monitoring System, K213919, 2022.

    Source note · manufacturer labeling

  7. 7. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603.

    Source note · peer-reviewed literature

  8. 8. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640.

    Source note · peer-reviewed literature

  9. 9. Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care. 2018;41(11):2275-2280.

    Source note · peer-reviewed literature

  10. 10. CLSI. POCT06: Effects of Different Sample Types on Glucose Measurements. Clinical and Laboratory Standards Institute.

    Source note · consensus standard